Shandong Taitian New Drug Development

Shandong Taitian New Drug Development is a clinical-stage biopharmaceutical company headquartered in Jinan, China, specializing in the development of novel small molecule drugs for autoimmune, inflammatory, and metabolic diseases. The company's pipeline is led by TT-0631, a Janus kinase (JAK) inhibitor currently in Phase 2 clinical trials for rheumatoid arthritis and atopic dermatitis. Another key program, TT-0168, is a thyroid hormone receptor beta (THR-beta) agonist being evaluated for the treatment of nonalcoholic steatohepatitis (NASH). Additionally, the company is developing TT-0343, a Tyrosine kinase 2 (TYK2) inhibitor for various inflammatory conditions. Shandong Taitian leverages its internal research platform to create high-quality candidates aimed at global markets.